Augurex Life Sciences Corp.

05/29/2026

Augurex has been named a finalist in the ADLM 2026 Disruptive Technology Award competition for SPINEstat® (Anti-14-3-3eta Multiplex).

Presented by the (Association for Diagnostics and Laboratory Medicine), this highly competitive award program recognizes technologies with the potential to advance laboratory medicine and improve patient care. Advancing from semi-finalist to finalist reflects the scientific merit, clinical relevance, and transformative impact of SPINEstat®, a first-in-class biomarker-based diagnostic test designed to support earlier identification of axial spondyloarthritis (axSpA) and differentiate inflammatory disease from mechanical back pain.

As a finalist, Augurex will present at ADLM 2026 on July 27 in Anaheim, CA, where the winner will be announced, and will showcase SPINEstat® at the ADLM Clinical Lab Expo July 28-30.

We are grateful for the recognition from ADLM and congratulate all finalists selected this year. Stay tuned!

Learn more about SPINEstat®: https://augurex.com/axial-spondyloarthritis/

Learn more about the award: https://meeting.myadlm.org/conference-program/disruptive-technology-award/contestants

05/20/2026

May 20 marks , highlighting conditions where the immune system drives inflammation, pain, and joint damage.

These diseases are complex, and early diagnosis is not always straightforward.

Better insight into underlying disease biology can help bring clarity earlier.

At Augurex, we are advancing biomarker approaches such as JOINTstat® (14-3-3eta) for rheumatoid arthritis and SPINEstat® (anti-14-3-3eta Multiplex) for axial spondyloarthritis to support more informed clinical decisions across and autoimmune disease care.

05/04/2026

May is , a reminder that arthritis is more than joint pain. It is a progressive disease that can lead to irreversible damage and loss of function if not identified and managed early.

Earlier insight matters.

At Augurex, solutions like JOINTstat® (14-3-3eta) and SPINEstat® (anti-14-3-3eta Multiplex) are helping bring greater clarity to disease risk and support more informed clinical decisions in and better patient management.

05/02/2026

May 2nd is , focused on ankylosing spondylitis, a form of axial spondyloarthritis that can lead to debilitating spinal mobility issues.

It often begins in early adulthood with persistent back pain, stiffness, and fatigue, yet diagnosis can take 7 to 10 years.

Many patients are initially told their symptoms are mechanical, while underlying inflammatory disease continues to progress.

Raising awareness of ankylosing spondylitis and the broader spectrum is critical, but improving how these conditions are recognized earlier is what ultimately changes outcomes in patient care.

05/02/2026

As part of , there is growing recognition that these diseases are often under-identified in routine care.

Many patients experience prolonged and uncertain journeys before reaching the right diagnosis, delaying access to appropriate treatment.

At Augurex, we are advancing diagnostic solutions like SPINEstat® (anti-14-3-3eta Multiplex) are designed to bring greater clarity to inflammatory disease, helping support earlier identification and more confident clinical decision-making across to improve patient outcomes.

04/29/2026

Augurex will be attending the Spondyloarthritis Research and Treatment Network (SPARTAN) 2026 Annual Meeting, May 14 - 16 in Toronto.

SPARTAN brings together leading rheumatologists dedicated to advancing research and care in axial spondyloarthritis (axSpA). We’re proud to engage with and support this community with SPINEstat®, a first-in-class diagnostic test designed to enable earlier identification of axSpA and differentiate it from mechanical back pain.

If you’re attending and would like to connect, please reach out to Chahal to coordinate a meeting during the conference.

Looking forward to engaging discussions and new connections. Let’s connect at SPARTAN 2026.

Read more in our press release: https://augurex.com/augurex-to-attend-spartan-2026-annual-meeting/

04/22/2026

Augurex will be attending the Northwest Rheumatism Society Annual Meeting, taking place April 30 – May 2, 2026 in Vancouver, Canada.We look forward to connecting with rheumatology clinicians and researchers from across the Pacific Northwest to discuss advances in inflammatory arthritis and the role of biomarker-driven diagnostics in supporting earlier and more informed care decisions.

If you’re attending the meeting, we’d welcome the opportunity to connect. Please reach out directly to Klompas or Bleakley to coordinate a time during the conference.

Learn more about the meeting: https://nwrsmeeting.org/

04/16/2026

Augurex will be attending and exhibiting at the Congress of Clinical Rheumatology (CCR) East 2026, April 30 - May 3 in Destin, FL.

Visit us at Booth 64 to learn more about our biomarker-driven diagnostic solutions designed to support earlier identification, risk stratification, and more confident care decisions in inflammatory arthritis.

Our diagnostic solutions include:

• JOINTstat® (14-3-3eta): A modifiable biomarker for diagnosis, prognosis, and monitoring of rheumatoid arthritis.

• SPINEstat® (Anti-14-3-3eta Multiplex): a first-in-class test to aid in the diagnosis of axial spondyloarthritis and help differentiate from mechanical back pain.

We look forward to engaging with community rheumatology providers and discussing how biomarker-based tools can complement clinical assessment and existing laboratory markers.

If you’re attending CCR East, stop by our booth or reach out to Mazinani to schedule time to connect.

Read more: https://augurex.com/augurex-to-exhibit-at-ccr-east-2026/

04/15/2026

We’re honored to be included as a semifinalist in the 2026 ADLM Disruptive Technology Award competition.

Thank you to the for Diagnostics and Laboratory Medicine for recognizing SPINEstat® (Anti-14-3-3eta Multiplex), our biomarker-based diagnostic designed to support earlier identification of axial spondyloarthritis and help differentiate inflammatory disease from mechanical back pain.

It’s a privilege to be recognized alongside an impressive group of innovators advancing laboratory medicine and patient care. Congratulations to all the semifinalists announced today.

We are thrilled to announce the semifinalists for the 2026 Disruptive Technology Award Competition! These gamechangers developed innovative and cutting-edge diagnostic solutions to improve patient care.

• In Diagnostics: single-use direct-to-consumer fingerstick panel via low-cost USB dongle and smartphone.

• Anvil Diagnostics: pan-fungal digital PCR blood test for broad pathogen identification.

• Prolight Diagnostics: point-of-care high-sensitivity troponin immunoassay that uses single-molecule counting.

• MADx: big-data multiplex IgE test generating comprehensive allergy profiles.

• Augurex Life Sciences: blood test detecting autoantibody-driven disease in back pain patients.

• Kompass Diagnostics: palm-sized multimodal platform for clinical-grade hormone testing.

Learn more about their solutions: https://ow.ly/pW3v50YJ46l

04/14/2026

We’re proud to share that Augurex has been selected as a semifinalist in the ADLM 2026 Disruptive Technology Award competition for SPINEstat® (Anti-14-3-3eta Multiplex).

Presented by the for Diagnostics and Laboratory Medicine, this highly competitive program recognizes technologies with significant potential to advance laboratory medicine and improve patient care.

SPINEstat® is a first-in-class biomarker-based diagnostic test designed to support earlier identification of axial spondyloarthritis (axSpA) and help differentiate inflammatory disease from mechanical back pain, a key challenge contributing to extended diagnostic delays for this potentially debilitating autoimmune disease that persists around the world.

We appreciate the recognition from ADLM and congratulate the other semifinalists selected this year. Looking forward to what comes next!

Learn more about the ADLM Disruptive Technology Award: https://meeting.myadlm.org/conference-program/disruptive-technology-award/contestants